Transcription-factor-modulating agents: Precision and selectivity in drug design

Molecular Medicine Today

Volumn 4, Issue 8, 1998, Pages 358-366

  Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DNA BINDING PROTEIN; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SOMATOMEDIN C; STAT4 PROTEIN; TAMOXIFEN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA3; TROGLITAZONE;

CELL DIFFERENTIATION; CELL GROWTH; COMPUTER AIDED DESIGN; DNA SEQUENCE; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; GENETIC ENGINEERING; HUMAN; NONHUMAN; REVIEW;

EID: 0031870368     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01303-3     Document Type: Review

References (38)

1. Tjian R. The biochemistry of transcription in eukaryotes: a paradigm for multisubunit regulatory complexes. Philos. Trans. R. Soc. London Ser. B. 351:1996;491-499.
2. Latchman, D.S. (1995) Transcriptional control - DNA sequence elements, in Gene Regulation (2nd edn) (Latchman, D.S., ed.), pp. 142-178, Chapman & Hall.
3. Vellanoweth R.L., Supakar P.C., Roy A.K. Transcription factors in development, growth and aging. Lab. Invest. 70:1994;784-799.
4. Faisst S., Meyer S. Compilation of vertebrate encoded transcription factors. Nucleic Acids Res. 20:1992;3-26.
5. Papavassiliou A.G. Transcription factors. N. Engl. J. Med. 332:1995;45-47.
6. Ouzounis, C.A. and Papavassiliou, A.G. (1997) DNA-binding motifs of eukaryotic transcription factors, in Transcription Factors in Eukaryotes (Papavassiliou, A.G., ed.), pp. 1-21, Landes Bioscience (Molecular Biology Intelligence Unit.
7. Latchman, D.S. (1995) Activation and repression of gene expression by transcription factors, in Eukaryotic Transcription Factors (2nd edn), pp. 239-278, Academic Press.
8. Latchman, D.S. (1995) Transcriptional control - transcription factors, in Gene Regulation (2nd edn) (Latchman, D.S., ed.), pp. 179-230, Chapman & Hall.
9. Treier, M. and Bohmann, D. (1996) Phosphorylation of transcription factors, in Protein Phosphorylation (Marks, F., ed.), pp. 297-327, VCH Publishers.
10. Calkhoven C.F., Ab G. Multiple steps in the regulation of transcription-factor level and activity. Biochem. J. 317:1996;329-342.
11. Creighton, T.E. (1993) Interactions with other molecules, in Proteins: Structures and Molecular Properties (2nd edn) (Creighton, T.E., ed.), pp. 329-384, W.H. Freeman.
12. Travers, A. (1993) DNA-protein interactions: sequence specific recognition, in DNA-Protein Interactions (Travers, A., ed.), pp. 52-86, Chapman & Hall.
13. Tjian R., Maniatis T. Transcriptional activation: A complex puzzle with few easy pieces. Cell. 77:1994;5-8.
14. Blundell T.L. Structure-based drug design. Nature. 384(Suppl. 6604):1996;23-26.
15. Peisach E.et al. Interaction of a peptidomimetic aminimide inhibitor with elastase. Science. 269:1995;66-69.
16. Desjarlais R.L.et al. Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure. J. Med. Chem. 31:1988;722-729.
17. Sudarsanam S., Virca G.D., March C.J., Srinivasan S. An approach to computer-aided inhibitor design: Application to cathepsin L. J. Comput.-Aided Mol. Design. 6:1992;223-233.
18. Lawrence M.C., Davis P.C. CLIX: A search algorithm for finding novel ligands capable of binding proteins of known three-dimensional structure. Proteins. 12:1992;31-41.
19. Maulik, S. and Patel, S.D. (1997) Protein engineering and computer-assisted drug design, in Molecular Biotechnology - Therapeutic Applications and Strategies (Maulik, S. and Patel, S.D., eds), pp. 109-153, Wiley-Liss.
20. Kuntz I.D.et al. Advances in computer-aided design of enzyme inhibitors. Abstracts of Papers Am. Chem. Soc. 203(1-3):1992;MED16.
21. Testa B.et al. Lipophilicity in molecular modeling. Pharm. Res. 13:1996;335-343.
22. Rotstein S.H., Murcko M.A. GenStar: A method for de novo drug design. J. Comput.-Aided Mol. Design. 7:1993;23-43.
23. Neidle S. Discovery of new anticancer drugs by computer-aided drug design. Ann. Oncol. 5(Suppl. 4):1994;S51-S54.
24. Papavassiliou A.G. Transcription factor-based drug design in anticancer drug development. Mol. Med. 3:1997;799-810.
25. Darnell J.E. Jr. STATs and gene regulation. Science. 277:1997;1630-1635.
26. Cohen G.B., Ren R., Baltimore D. Modular binding domains in signal transduction proteins. Cell. 80:1995;237-248.
27. Stahl N.et al. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science. 267:1995;1349-1353.
28. Heim M.H., Kerr I.M., Stark G.R., Darnell J.E. Jr. Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science. 267:1995;1347-1349.
29. Gilman, M. and Vignais, M-L. (1997) The STAT family of transcription factors, in Transcription Factors in Eukaryotes (Papavassiliou, A.G., ed.), pp. 125-138, Landes Bioscience (Molecular Biology Intelligence Unit).
30. Schreck, R., Kistler, B. and Wirth, T. (1997) The NF-κB/rel system of transcriptional activators, in Transcription Factors in Eukaryotes (Papavassiliou, A.G., ed.), pp. 153-188, Landes Bioscience (Molecular Biology Intelligence Unit).
31. Baldwin A.S. Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14:1996;649-683.
32. Müller C.W.et al. Structure of the NF-κB p50 homodimer bound to DNA. Nature. 373:1995;311-317.
33. Beg A.A.et al. IκB interacts with the nuclear localization sequences of the subunits of NF-κB: a mechanism for cytoplasmic retention. Genes Dev. 6:1992;1899-1913.
34. Traenckner E.B-M.et al. Phosphorylation of human IκB-α on serines 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J. 14:1995;2876-2883.
35. 2 is a ligand for the adipocyte determination factor PPARγ Cell. 83:1995;803-812.
36. Cai W., Hu L., Foulkes J.D. Transcription-modulating drugs: mechanism and selectivity. Curr. Opin. Biotechnol. 7:1996;608-615.
37. Schwartz S., Raskin P., Fonseca V., Graveline J.F. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. New Engl. J. Med. 338:1998;861-866.
38. Draper M.W.et al. A controlled trial of raloxifene (LY139481)HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 11:1996;835-842.